Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 72

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 72
---
Basic and diluted net income per common share$0.10 $0.19 The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):Three Months EndedMarch 31,20252024Weighted average number of stock options6,677 7,662 2025 Notes if-converted method adjustment2,821 — Weighted average number of RSUs2,363 1,230 Weighted average ESPP share options— 52       Total11,861 8,944 

NOTE 14—INCOME TAXES

Income (loss) before income taxes and income tax expense are as follows (dollar amounts in thousands):Three Months EndedMarch 31,20252024Income (loss) before income taxes:   Domestic$10,673 $13,657    Foreign(1,967)(17)Total income before income taxes$8,706 $13,640 Income tax expense$3,894 $4,661 Effective tax rate45 %34 %

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 28

The Company’s income tax expense represents the estimated annual effective tax rate applied to the year-to-date domestic operating results, adjusted for certain discrete tax items.The Company’s effective tax rate for the three months ended March 31, 2025 was primarily impacted by costs related to non-deductible executive compensation, non-deductible stock-based compensation and a non-U.S. valuation allowance, partially offset by tax credits.The Company’s effective tax rate for the three months ended March 31, 2024 includes costs related to non-deductible stock-based compensation and non-deductible executive compensation, partially offset by tax credits and a fair value adjustment for contingent consideration.As of both March 31, 2025 and December 31, 2024, the Company had an income tax payable balance of $5.1 million that was included in other liabilities within the condensed consolidated balance sheet. As of March 31, 2025 and December 31, 2024, the Company has $1.5 million and $0.7 million, respectively, of current income taxes payable that is included in accrued expenses within the